Supernus Pharmaceuticals (SUPN) Interest Coverage Ratio: History & Chart

Supernus Pharmaceuticals, Inc.(SUPN)

Drug Manufacturers - Specialty & Generic · Rockville, MD

$42.83+0.07 (+0.16%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.

Rockville, MD

778 employees

www.supernus.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Jack A. Khattar

View full financials

SUPN Interest Coverage Ratio Metrics

INTEREST COVERAGE RATIO

-25.04x

INTEREST COVERAGE RATIO AVG TTM

N/A

INTEREST COVERAGE RATIO AVG 3Y

-22.18x

INTEREST COVERAGE RATIO AVG 5Y

-0.02x

INTEREST COVERAGE RATIO AVG 10Y

8.07x

INTEREST COVERAGE RATIO AVG 15Y

2.94x

INTEREST COVERAGE RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

-12.87%

CURRENT VS 5Y AVG

-115035.74%

CURRENT VS 10Y AVG

-410.21%

CURRENT VS 15Y AVG

-950.72%

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

-6.38x

median of 528 covered companies

CURRENT VS SECTOR MEDIAN

-292.75%

vs the sector median at left

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
Supernus Pharmaceuticals, Inc. (SUPN)	$2.49B	-25.04x	N/A	-22.18x	-0.02x
Recursion Pharmaceuticals, Inc. (RXRX)vs ›	$2.43B	-358.08x	N/A	N/A	N/A
Privia Health Group, Inc. (PRVA)vs ›	$2.56B	N/A	7.78x	5.30x	5.30x
Clover Health Investments, Corp. (CLOV)vs ›	$2.38B	N/A	N/A	N/A	N/A
Beam Therapeutics Inc. (BEAM)vs ›	$2.60B	-8.77x	N/A	N/A	N/A
NewAmsterdam Pharma Company N.V. (NAMS)vs ›	$2.60B	N/A	N/A	N/A	N/A
Disc Medicine, Inc. (IRON)vs ›	$2.37B	-65.43x	N/A	N/A	N/A
Neogen Corporation (NEOG)vs ›	$2.61B	-0.37x	0.59x	204.00x	353.37x
ADMA Biologics, Inc. (ADMA)vs ›	$2.36B	26.93x	18.45x	12.59x	12.59x
Nurix Therapeutics, Inc. (NRIX)vs ›	$2.35B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

Supernus Pharmaceuticals, Inc. (SUPN)

$2.49B

-25.04x

N/A

-22.18x

-0.02x

Recursion Pharmaceuticals, Inc. (RXRX)vs ›

$2.43B

-358.08x

N/A

Privia Health Group, Inc. (PRVA)vs ›

$2.56B

N/A

7.78x

5.30x

Clover Health Investments, Corp. (CLOV)vs ›

$2.38B

N/A

Beam Therapeutics Inc. (BEAM)vs ›

$2.60B

-8.77x

N/A

NewAmsterdam Pharma Company N.V. (NAMS)vs ›

$2.60B

N/A

Disc Medicine, Inc. (IRON)vs ›

$2.37B

-65.43x

N/A

Neogen Corporation (NEOG)vs ›

$2.61B

-0.37x

0.59x

204.00x

353.37x

ADMA Biologics, Inc. (ADMA)vs ›

$2.36B

26.93x

18.45x

12.59x

Nurix Therapeutics, Inc. (NRIX)vs ›

$2.35B

N/A

Interest Coverage Ratio FAQ

What is the interest coverage ratio for Supernus Pharmaceuticals, Inc. (SUPN)?

The interest coverage ratio for SUPN stock is -25.04x.

Is Supernus Pharmaceuticals, Inc.'s interest coverage ratio high or low?

The interest coverage ratio of -25.04x is 115036% below its 5-year average of -0.02x, near the low end of its 5-year range (-25.04x–21.54x).

What is the 3Y average interest coverage ratio for Supernus Pharmaceuticals, Inc. (SUPN)?

The 3Y average interest coverage ratio for SUPN stock is -22.18x.

What is the 5Y average interest coverage ratio for Supernus Pharmaceuticals, Inc. (SUPN)?

The 5Y average interest coverage ratio for SUPN stock is -0.02x.

What is the 10Y average interest coverage ratio for Supernus Pharmaceuticals, Inc. (SUPN)?

The 10Y average interest coverage ratio for SUPN stock is 8.07x.

What is the 15Y average interest coverage ratio for Supernus Pharmaceuticals, Inc. (SUPN)?

The 15Y average interest coverage ratio for SUPN stock is 2.94x.

DATE	INTEREST COVERAGE RATIO
2026-06-30	-25.04x
2023-06-30	-19.33x
2023-03-31	3.44x
2022-12-31	21.54x
2022-09-30	-0.88x
2022-06-30	6.27x
2022-03-31	1.01x
2021-12-31	1.03x
2021-09-30	5.50x
2021-06-30	6.24x
2021-03-31	2.17x
2020-12-31	7.05x
2020-09-30	9.22x
2020-06-30	7.83x
2020-03-31	5.04x
2019-12-31	6.95x
2019-09-30	7.02x
2019-06-30	7.90x
2019-03-31	4.33x
2018-12-31	7.12x
2018-09-30	6.73x
2018-06-30	6.46x
2018-03-31	22.14x
2017-12-31	214.65x
2017-09-30	144.14x
2017-06-30	119.57x
2017-03-31	16.00x
2016-12-31	17.14x
2016-09-30	16.45x
2016-06-30	53.27x
2016-03-31	29.71x
2015-12-31	30.44x
2015-09-30	14.76x
2015-06-30	9.29x
2015-03-31	9.00x
2014-12-31	3.98x
2014-09-30	22.63x
2014-06-30	2.94x
2014-03-31	-11.12x
2013-12-31	-5.39x
2013-09-30	-5.98x
2013-06-30	-7.22x
2013-03-31	-24.63x
2012-12-31	-15.85x
2012-09-30	-13.97x
2012-06-30	-9.96x
2012-03-31	-8.19x
2011-12-31	2.31x
2011-09-30	-19.87x
2011-06-30	-16.83x
2011-03-31	-25.55x
2009-12-31	1.49x

DATE

INTEREST COVERAGE RATIO

2026-06-30

-25.04x

2023-06-30

-19.33x

2023-03-31

3.44x

2022-12-31

21.54x

2022-09-30

-0.88x

2022-06-30

6.27x

2022-03-31

1.01x

2021-12-31

1.03x

2021-09-30

5.50x

2021-06-30

6.24x

2021-03-31

2.17x

2020-12-31

7.05x

2020-09-30

9.22x

2020-06-30

7.83x

2020-03-31

5.04x

2019-12-31

6.95x

2019-09-30

7.02x

2019-06-30

7.90x

2019-03-31

4.33x

2018-12-31

7.12x

2018-09-30

6.73x

2018-06-30

6.46x

2018-03-31

22.14x

2017-12-31

214.65x

2017-09-30

144.14x

2017-06-30

119.57x

2017-03-31

16.00x

2016-12-31

17.14x

2016-09-30

16.45x

2016-06-30

53.27x

2016-03-31

29.71x

2015-12-31

30.44x

2015-09-30

14.76x

2015-06-30

9.29x

2015-03-31

9.00x

2014-12-31

3.98x

2014-09-30

22.63x

2014-06-30

2.94x

2014-03-31

-11.12x

2013-12-31

-5.39x

2013-09-30

-5.98x

2013-06-30

-7.22x

2013-03-31

-24.63x

2012-12-31

-15.85x

2012-09-30

-13.97x

2012-06-30

-9.96x

2012-03-31

-8.19x

2011-12-31

2.31x

2011-09-30

-19.87x

2011-06-30

-16.83x

2011-03-31

-25.55x

2009-12-31

1.49x

Interest Coverage Ratio: -25.04x

SUPN Interest Coverage Ratio

SUPN Average Interest Coverage Ratio Chart

SUPN Current vs Average Interest Coverage Ratio Chart

SUPN Interest Coverage Ratio Metrics

SUPN Competitors' Interest Coverage Ratio

Financial Health Indicators

Interest Coverage Ratio Formula & Definition

Interest Coverage Ratio FAQ

SUPN Interest Coverage Ratio History

Related Metrics